A rapid review of differences in cerebrospinal neurofilament light levels in clinical subtypes of progressive multiple sclerosis

• Published in: Frontiers in neurology 2024-04, Vol.15, p.1382468-1382468
• Main Authors: Desu, Haritha L, Sawicka, Katherine M, Wuerch, Emily, Kitchin, Vanessa, Quandt, Jacqueline A
• Format: Article
• Language: English
• Subjects: biomarkers; multiple sclerosis; neurodegeneration; neurofilament light; Neurology; progression
• ISSN: 1664-2295; 1664-2295
• DOI: 10.3389/fneur.2024.1382468

Multiple sclerosis (MS) is divided into three clinical phenotypes: relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS). It is unknown to what extent SPMS and PPMS pathophysiology share inflammatory or neurodegenerative pathological processes. Cerebrospinal (CSF) neurofilament light (NfL) has been broadly studied in different MS phenotypes and is a candidate biomarker for comparing MS subtypes. Are CSF NfL levels different among clinical subtypes of progressive MS? A search strategy identifying original research investigating fluid neurodegenerative biomarkers in progressive forms of MS between 2010 and 2022 was applied to Medline. Identified articles underwent title and abstract screen and full text review against pre-specified criteria. Data abstraction was limited to studies that measured NfL levels in the CSF. Reported statistical comparisons of NfL levels between clinical phenotypes were abstracted qualitatively. 18 studies that focused on investigating direct comparisons of CSF NfL from people with MS were included in the final report. We found NfL levels were typically reported to be higher in relapsing and progressive MS compared to healthy controls. Notably, higher NfL levels were not clearly associated with progressive MS subtypes when compared to relapsing MS, and there was no observed difference in NfL levels between PPMS and SPMS in articles that separately assessed these phenotypes. CSF NfL levels distinguish individuals with MS from healthy controls but do not differentiate MS subtypes. Broad biological phenotyping is needed to overcome limitations of current clinical phenotyping and improve biomarker translatability to decision-making in the clinic.